Risk of hair loss associated with glucagon-like peptide-1 receptor agonists in adults with type 2 diabetes: target trial emulation

The authors aimed to investigate the association between glucagon-like peptide-1 (GLP-1) receptor agonists and the risk of hair loss (alopecia) in adults with type 2 diabetes, comparing it to sodium-glucose cotransporter-2 (SGLT-2) inhibitors and dipeptidyl peptidase-4 (DPP-4) inhibitors. The study found that the use of GLP-1 receptor agonists was linked to a higher risk of non-scarring alopecia compared to both SGLT-2 and DPP-4 inhibitors, suggesting that while the absolute risk is low, this potential side effect should be considered in treatment decisions.